Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average rating of “Hold” by the six analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $5.00.

Separately, Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a research report on Tuesday. They set an “equal weight” rating and a $5.00 price target for the company.

Zentalis Pharmaceuticals Stock Down 7.7%

Shares of ZNTL stock opened at $2.52 on Thursday. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $3.95. The stock has a market cap of $182.07 million, a PE ratio of -1.22 and a beta of 1.71. The business has a 50-day simple moving average of $2.68 and a 200-day simple moving average of $1.91.

Insider Buying and Selling

In other news, major shareholder Group Walters purchased 6,459,973 shares of the stock in a transaction that occurred on Wednesday, December 31st. The shares were purchased at an average cost of $1.20 per share, with a total value of $7,751,967.60. Following the completion of the acquisition, the insider owned 13,509,973 shares of the company’s stock, valued at approximately $16,211,967.60. This represents a 91.63% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Vincent Vultaggio sold 29,951 shares of the firm’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the sale, the insider owned 156,779 shares in the company, valued at approximately $380,972.97. This represents a 16.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 46,617 shares of company stock worth $113,417 in the last ninety days. Corporate insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Sivia Capital Partners LLC purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $27,000. Catalyst Funds Management Pty Ltd purchased a new position in Zentalis Pharmaceuticals during the second quarter worth approximately $31,000. Qube Research & Technologies Ltd acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $37,000. Corient Private Wealth LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter valued at approximately $41,000. Finally, Voleon Capital Management LP purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.